➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
McKesson
Mallinckrodt
Express Scripts

Last Updated: August 2, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JARDIANCE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for JARDIANCE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01001962 ↗ Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics Not yet recruiting Aristotle University Of Thessaloniki Phase 4 2016-01-01 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT02367131 ↗ Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus Active, not recruiting Eli Lilly and Company N/A 2015-02-01 Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
NCT02367131 ↗ Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus Active, not recruiting Boehringer Ingelheim N/A 2015-02-01 Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
NCT02401880 ↗ Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology Completed Profil Institut für Stoffwechselforschung GmbH Phase 4 2015-05-01 The primary aim of this exploratory mechanistic study is to investigate the effects of Empagliflozin and Linagliptin on alpha- and beta cell physiology in T2DM patients. This study aims to evaluate the effect of the DPP-IV inhibitor linagliptin (as compared to placebo) in addition to the SGLT-2 inhibitor empagliflozin on pancreatic alpha and beta cell function, as well as several markers of metabolic control.
NCT02471963 ↗ Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function Completed University of Erlangen-Nürnberg Medical School Phase 3 2014-12-01 Empagliflozin may lead to improved vascular and endothelial function in the macro- (pulse wave reflection) and microcirculation (retinal circulation) and improve cardiovascular risk factors, imparticular by effectively controlling hyperglycemia, arterial hypertension and obesity.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for JARDIANCE

Condition Name

Condition Name for JARDIANCE
Intervention Trials
Diabetes Mellitus, Type 2 7
Type 2 Diabetes Mellitus 6
Type 2 Diabetes 4
Type2 Diabetes 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for JARDIANCE
Intervention Trials
Diabetes Mellitus 27
Diabetes Mellitus, Type 2 26
Non-alcoholic Fatty Liver Disease 4
Heart Failure 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for JARDIANCE

Trials by Country

Trials by Country for JARDIANCE
Location Trials
Germany 7
Korea, Republic of 6
Switzerland 4
Japan 3
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for JARDIANCE
Location Trials
Ohio 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for JARDIANCE

Clinical Trial Phase

Clinical Trial Phase for JARDIANCE
Clinical Trial Phase Trials
Phase 4 23
Phase 3 6
Phase 2/Phase 3 3
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for JARDIANCE
Clinical Trial Phase Trials
Not yet recruiting 23
Recruiting 17
Completed 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for JARDIANCE

Sponsor Name

Sponsor Name for JARDIANCE
Sponsor Trials
Boehringer Ingelheim 12
Eli Lilly and Company 4
University Hospital, Basel, Switzerland 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for JARDIANCE
Sponsor Trials
Other 62
Industry 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Dow
Medtronic
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.